Hoth Therapeutics Reports Data For HT-001; No Serious Adverse Events

Hoth Therapeutics has reported data for its topical treatment HT-001, indicating limited systemic absorption with approximately 99% reduced systemic levels compared to FDA-approved oral formulations. The company noted that there were no serious adverse events associated with the treatment. This data may impact the company's future development and regulatory strategy for HT-001.